Compare ASTLW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASTLW | ERNAW |
|---|---|---|
| Founded | 1901 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | 2021 |
| Metric | ASTLW | ERNAW |
|---|---|---|
| Price | $0.01 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.6K | 23.5K |
| Earning Date | 02-18-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.00 | $0.02 |
| 52 Week High | $0.34 | $0.23 |
| Indicator | ASTLW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 53.73 |
| Support Level | $0.00 | $0.03 |
| Resistance Level | $0.01 | $0.08 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 29.90 | 76.37 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.